SYNAPS Dx Announces Prestigious Scientific Advisory Board to Guide Strategy and Commercialization of DISCERN™, Only Autopsy-Validated Test for Accurate Diagnosis of Alzheimer's Disease
View the full release here: https://www.businesswire.com/news/home/20240117576710/en/
- View the full release here: https://www.businesswire.com/news/home/20240117576710/en/
• Alberto J. Espay, MD, MSc, chairman of the SAB, has over 300 published peer-reviewed research articles and 10 books on neurodegenerative diseases. - • Giulio Taglialatela, PhD, serves as the vice chair for research of the Department of Neurology and the director of the UTMB Mitchell Center for Neurodegenerative Diseases.
- “We are honored to partner with such exceptional thought leaders who are shaping the future of brain health and advancing the biology of memory.
- The AD-biomarker index also composes one of the three assays and tests skin fibroblasts from biopsies to culture to confluency.